Additional file 3: of B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24Â weeks after initiation of rituximab treatment in rheumatoid arthritis patients

Appendix C. Quantitative tissue uptake of 89Zr-rituximab on whole body PET in responders vs. non-responders. An additional table with SUV of body organs like liver, spleen and vertebrae showing that there is no (significant) difference between responders and non-responders in organ uptake of 89Zr-rituximab. (DOCX 15Â kb)